Research location

Mexico City

Mexico

Published trials678
Site observations915
Linked trials published678
Page2 / 14

Research activity in Mexico City

Mexico

CureCurrent currently publishes aggregate city-level research activity for this location: 678 trials and 915 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Mexico City

678 linked trials · page 2 of 14
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21 · 2 site observations
RECRUITING
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)NCT06103864 · 2023-11-23 · 2 site observations
RECRUITING
ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673 · 2023-11-14 · 2 site observations
RECRUITING
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 · 2023-10-26 · 4 site observations
RECRUITING
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerNCT05894239 · 2023-09-08 · 1 site observation
RECRUITING
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaNCT06023589 · 2023-08-24 · 1 site observation
RECRUITING
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)NCT05427370 · 2023-06-22 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid TumorsNCT05544240 · 2023-02-01 · 1 site observation
RECRUITING
REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)NCT05665556 · 2022-12-15 · 1 site observation
RECRUITING
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR MutationsNCT05445791 · 2021-07-15 · 1 site observation
RECRUITING
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.NCT04766866 · 2021-03-02 · 1 site observation
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation
RECRUITING
Paradoxical Tuberculosis Reactions in Patients Without HIV InfectionNCT04052022 · 2019-12-20 · 2 site observations
RECRUITING
Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer PatientsNCT03803787 · 2018-09-01 · 2 site observations
RECRUITING
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesNCT03549754 · 2018-02-17 · 2 site observations
RECRUITING
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLCNCT02734069 · 2016-02-01 · 1 site observation
RECRUITING
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)NCT07595042 · 2026-10-30 · 1 site observation
NOT_YET_RECRUITING
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNCT07861100 · 2026-10-26 · 2 site observations
NOT_YET_RECRUITING
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 DiabetesNCT07628985 · 2026-09-01 · 1 site observation
NOT_YET_RECRUITING
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or ObesityNCT07622810 · 2026-09-01 · 1 site observation
NOT_YET_RECRUITING
Real-World Patient and Physician Experience With Semaglutide Across Six Emerging MarketsNCT07850765 · 2026-08-28 · 1 site observation
COMPLETED
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightNCT06962280 · 2025-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaNCT06664619 · 2024-12-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Nipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969 · 2024-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362 · 2024-11-21 · 1 site observation
COMPLETED
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · 2024-10-22 · 2 site observations
COMPLETED
Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's DiseaseNCT07417670 · 2024-10-04 · 1 site observation
COMPLETED
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerNCT06497556 · 2024-09-23 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and PleasureNCT06635135 · 2024-09-19 · 1 site observation
TERMINATED
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory PolyneuropathyNCT06568042 · 2024-08-22 · 1 site observation
COMPLETED
Use of Machine Learning Techniques for Serial Assessment of Systemic Inflammatory Markers in Breast Cancer PatientsNCT06447532 · 2024-08-01 · 1 site observation
ENROLLING_BY_INVITATION
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)NCT06472076 · 2024-06-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's SyndromeNCT06312020 · 2024-05-09 · 1 site observation
TERMINATED
Effect of an Intervention With Apple Cider Vinegar on Glycemic Variability and Lipid Profile in Patients With Type 2 Diabetes MellitusNCT07493707 · 2024-05-06 · 1 site observation
ACTIVE_NOT_RECRUITING
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 4 site observations
ACTIVE_NOT_RECRUITING
NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer PatientsNCT06131424 · 2024-04-23 · 1 site observation
COMPLETED
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung CancerNCT06348199 · 2024-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Digital Health Intervention to Improve Health Care and Outcomes for Breast Cancer PatientsNCT05925257 · 2024-03-05 · 1 site observation
UNKNOWN
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentNCT06151574 · 2024-02-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Chrono Nutrition and Insulin Resistance in DiabetesNCT06163248 · 2024-01-01 · 1 site observation
UNKNOWN
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)NCT05934526 · 2023-12-28 · 1 site observation
COMPLETED
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473 · 2023-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11 · 2 site observations
ACTIVE_NOT_RECRUITING
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisNCT06025578 · 2023-10-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected AdultsNCT06039579 · 2023-10-25 · 1 site observation
COMPLETED
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsNCT06040086 · 2023-09-22 · 1 site observation
COMPLETED
Mechanisms and Phenotypes of Hypertension in Patients in Chronic HemodialysisNCT06764277 · 2023-08-14 · 1 site observation
COMPLETED

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.